Get the Stockscreener App
206.68
0.80%
-1.67
Axsome Therapeutics Inc stock is traded at $206.68, with a volume of 438.24K.
It is down -0.80% in the last 24 hours and down -2.59% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$208.35
Open:
$207.01
24h Volume:
438.24K
Relative Volume:
0.52
Market Cap:
$10.83B
Revenue:
$708.24M
Net Income/Loss:
$-188.30M
P/E Ratio:
-55.27
EPS:
-3.7392
Net Cash Flow:
$-70.99M
1W Performance:
+3.85%
1M Performance:
-2.59%
6M Performance:
+25.96%
1Y Performance:
+66.13%
1-Day Range:
$205.49
$208.51
1-Week Range:
$197.05
$210.59
52-Week Range:
$112.90
$260.19
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
206.68 | 10.90B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Initiated | Oppenheimer | Outperform |
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Enterprise value to EBIT forward of Axsome Therapeutics, Inc. – MUN:19X - TradingView
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism? - Stocktwits
AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug This Week - Stocktwits
Zacks Research Upgrades Axsome Therapeutics (NASDAQ:AXSM) to "Hold" - MarketBeat
Lisanti Capital Growth LLC Acquires Shares of 20,825 Axsome Therapeutics, Inc. $AXSM - MarketBeat
Eagle Health Investments LP Invests $15.92 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Enterprise value to EBITDA forward of Axsome Therapeutics, Inc. – SWB:19X - TradingView
Axsome Therapeutics Inc (AXSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years - Sahm
Pallas Capital Advisors LLC Acquires Shares of 40,511 Axsome Therapeutics, Inc. $AXSM - MarketBeat
TimesSquare Capital Management LLC Takes Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
AXSM Stock Advances On CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030 - Stocktwits
OneDigital Investment Advisors LLC Makes New Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Significant 33.58% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
GSA Capital Partners LLP Makes New $2.31 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. (AXSM) Latest Stock News & Headlines - Yahoo Finance
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $316 - Moomoo
Handelsbanken Fonder AB Has $10.38 Million Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today - Sahm
AXSM|Axsome Therapeutics Inc|Price:213.630|Chg%:-1.030 - TradingKey
Axsome Therapeutics (NASDAQ:AXSM) Faces A Crucial Test - Kalkine Media
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - simplywall.st
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
AXSOME THERAPEUTICS, INC. : MIZUHO RAISES TARGET PRICE TO $316 FROM $306 - webull.com
UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating - Moomoo
Mizuho raises Axsome Therapeutics stock price target on Auvelity By Investing.com - Investing.com South Africa
Mizuho raises Axsome Therapeutics stock price target on Auvelity - Investing.com
Mizuho Adjusts PT on Axsome Therapeutics to $316 From $306, Keeps Outperform Rating - marketscreener.com
Quantinno Capital Management LP Acquires 5,019 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results - webull.com
AXSOME THERAPEUTICS, INC. : MORGAN STANLEY RAISES TARGET PRICE TO $251 FROM $242 - webull.com
Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues - Yahoo Finance
Axsome Therapeutics (AXSM) Shares Just Climbed, So What Is Driving Attention Now? - Yahoo Finance
RBC cuts Axsome Therapeutics stock price target on model updates By Investing.com - Investing.com Australia
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition (AXSM) - Seeking Alpha
Axsome's Auvelity Strength Expected to Drive H2 Revenue Growth, RBC Says - marketscreener.com
Axsome Therapeutics Is Maintained at Outperform by RBC Capital - Moomoo
Wells Fargo raises Axsome Therapeutics price target to $256 By Investing.com - Investing.com Australia
RBC cuts Axsome Therapeutics stock price target on model updates - Investing.com
Needham raises Axsome Therapeutics stock price target on drug growth By Investing.com - Investing.com South Africa
AXSM Maintained by Wells Fargo -- Price Target Raised to $256 - GuruFocus
Guggenheim raises Axsome Therapeutics stock price target on sales beat By Investing.com - Investing.com Nigeria
Needham raises Axsome Therapeutics stock price target on drug growth - Investing.com
Morgan Stanley Adjusts Axsome Therapeutics PT to $251 From $242, Keeps Equalweight Rating - marketscreener.com
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $268.00 - MarketBeat
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axsome Therapeutics Inc Stock (AXSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
Sep 03 '26 |
Sale |
208.65 |
10,000 |
2,086,500 |
0 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):